Navigation Links
The Rottenstein Law Group LLP Notes Lifelong Side Effects of DES Can Lead to Cancer
Date:5/31/2013

(PRWEB) May 31, 2013

Diethylstilbestrol (DES), a synthetic hormone previously manufactured by several companies and formerly prescribed to pregnant women to prevent miscarriages and premature births, could potentially cause cancer in those women’s children. The Rottenstein Law Group LLP acknowledges a Centers for Disease Control report of the struggles of "DES Daughters" with a series of life-threatening cancers related to their mother’s use of the drug while pregnant. The firm maintains a DES Cancer Lawsuit Center at http://www.descancerlawsuit.com that features more details about lawsuits and the side effects of the drug.

The CDC report* notes ongoing research into the manifestation of "clear cell adenocarcinoma, structural abnormalities in the reproductive organs, infertility and pregnancy complications."

Rottenstein Law Group LLP Principal Rochelle Rottenstein comments on the research and how it relates to the communication she has received from those looking to file DES lawsuits.

“The first DES cancer lawsuits began as far back as the 1970s, but recently there have been more suits filed because of the drug’s serious alleged lifelong side effects,” Rottenstein said. “Some side effects don’t show up until later in the lives of so-called DES children and grandchildren.”

DES was prescribed to more than 10 million women from the 1940s to the 1970s to prevent miscarriages and premature births. Use of the drug by pregnant mothers allegedly led to their children experiencing cancer, infertility, and pregnancy difficulties, according to the National Cancer Institute.**

In 2013 about 51 women have filed suits in Boston against a dozen manufacturers or marketers of the drug, according to the Associated Press.*** One lawsuit was settled in January 2013 after a day at trial (1:11-cv-10152-MBB in the U.S. District Court for the District of Massachusetts).

The Rottenstein Law Group LLP encourages those who believe they have suffered DES side effects to visit its page dedicated to providing information about the DES link to certain types of cancers reportedly related to a pregnant woman’s use of the drug.

*cdc.gov/des/consumers/about/concerns_daughters.html
**cancer.gov/cancertopics/factsheet/Risk/DES
***sentinelandenterprise.com/breakingnews/ci_22341598/ap-settlement-reached-mass-lawsuit-pregnancy-drug (January 2013)

For the latest news on defective medications and medical devices and related lawsuits, visit the Rottenstein Law Group LLP’s Injury Lawyer Newswire at injurylawyernewswire.com. Readers can subscribe to the news site’s stories and videos to stay on top of personal injury news.

About THE ROTTENSTEIN LAW GROUP LLP
The Rottenstein Law Group LLP is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices and medications. (Attorney advertising. Prior results do not guarantee a similar outcome.)

Contact:
The Rottenstein Law Group LLP
Rochelle Rottenstein, Esq.
321 W. 44th Street
# 804
New York NY 10036
(212) 933-9500 (office phone)
(212) 933-9980 (facsimile)
rochelle (at) rotlaw (dot) com

                            ###

Read the full story at http://www.prweb.com/releases/des-lawsuit/des-cancer/prweb10786743.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. FDA Says Metal-on-Metal Hip Replacements Can Cause Soft-Tissue Damage, Rottenstein Law Group Reports
2. Stryker Hip Replacement Lawsuit News: Mass. Woman Files First Known Federal Stryker ABG II Hip Lawsuit, Rottenstein Law Group Reports
3. DePuy ASR Lawsuit Update: Rottenstein Law Group Addresses J&J Motion to Appeal $8.3 Million Verdict
4. Fosamax Lawsuits Update: Rottenstein Law Group Responds to Femur Fracture Verdict in Merck’s Favor
5. Da Vinci Surgical Robot Lawsuit News: Rottenstein Law Group Comments on Testimony in Ongoing Robot Trial
6. Rottenstein Law Group Notes Medical Journal Article Advising Doctors To Use Caution When Prescribing Zithromax and Other Antibiotics
7. NuvaRing Lawsuit News: Rottenstein Law Group Responds to Judge’s Refusal to Dismiss Punitive Damages Claims
8. Lipitor Lawsuit News: Rottenstein Law Group Comments on FDA Approval of New Drug With Lipitor Compound
9. DePuy ASR Lawsuit Update: Rottenstein Law Group Comments on Delay of Second Federal Trial
10. Lipitor Lawsuit News: US Spending on Drugs Fell For First Time in 2012, Notes Rottenstein Law Group LLP
11. Da Vinci Surgical Robot Lawsuit News: Robot Maker Says Device Could Cause Internal Burns, Notes Rottenstein Law Group LLP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... ... With the increasing demand for dental implants, the National Association of Dental Laboratories ( ... patients about the safety issues related to dental restorations. According to the American Academy ... to reach $6.4 billion in 2018 with more than 30 million Americans missing all ...
(Date:12/8/2016)... ... 08, 2016 , ... Catalent Pharma Solutions, the leading global ... health products, today announced that it had joined the Pharmaceutical Supply Chain Initiative ... to unite pharmaceutical and healthcare companies that share a vision of better, social, ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Care Act. Dr. Botelho advocates for the mass media launching of story movements ... ongoing opportunities to share their unfortunate experiences; such a movement can generate the ...
(Date:12/8/2016)... ... December 08, 2016 , ... Peter ... communities in and around the greater Phoenix metropolitan region, is announcing a charity ... The mission of the Homeless Youth Connection is to promote community awareness of ...
(Date:12/7/2016)... ... December 07, 2016 , ... DrugDev again ... that it is one of the early adopters completing EU-U.S. Privacy Shield Certification from ... to provide companies on both sides of the Atlantic with a mechanism to comply ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals International, ... VRX) ("Valeant") today announced positive results from a ... to assess the safety and efficacy of IDP-118 ... of plaque psoriasis. Within the ... moderate to severe psoriasis, IDP-118 showed statistical significance ...
(Date:12/8/2016)... 8, 2016  EIP Pharma, LLC ( www.eippharma.com ... for neflamapimod (previously code named VX-745), with the ... trials that demonstrated significant Alzheimer,s disease relevant pharmacological ... and Study 303 (6-week treatment) are the subject ... Disease (CTAD) scientific conference in San ...
(Date:12/8/2016)... 2016 A Small Business Innovative Research (SBIR) ... Health (NIH) to Phoenix -based NeuroEM ... The grant will seek to determine an optimal set ... electromagnetic waves to treat Alzheimer,s Disease. The grant will ... possibly treat other neurologic disorders such as Parkinson,s Disease ...
Breaking Medicine Technology: